cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Myriad Genetics Inc
2 own
6 watching
Current Price
$19.72
$0.46
(2.39%)
logo-mygn
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,595.35M
52-Week High
52-Week High
28.18
52-Week Low
52-Week Low
13.92
Average Volume
Average Volume
0.67M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
22.73
iconMarket Capitalization1,595.35M
icon52-Week High28.18
icon52-Week Low13.92
iconAverage Volume0.67M
iconDividend Yield--
iconP/E Ratio22.73
What does the Myriad Genetics Inc do?
Myriad Genetics, Inc., a personalized medicine company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It operates through two segments, Diagnostics and Other. The Diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease; identify a patient's likelihood of responding to drug therapy; guide a patient's dosing to ensure optimal treatment; and assess a patient's risk of disease progression and disease recurrence. The Other segment provides testing products and services to the pharmaceutical, biotechnology, and medical research industries; and research and development, and clinical services for patients. Its molecular diagnostic DNA sequencing tests include myRisk Hereditary cancer, a test for hereditary cancers; BRACAnalysis and BART, which are tests for hereditary breast and ovarian cancers; BRACAnalysis CDx test for use in identifying ovarian cancer patients with suspected deleterious germline; and Tumor BRACAnalysis CDx test that is used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. The company also provides COLARIS test for colorectal and uterine cancers; COLARIS AP test for colorectal cancer; Vectra DA protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for prostate cancer; EndoPredict RNA expression test for breast cancer; myPath Melanoma RNA expression test for diagnosing melanoma; myChoice homologous recombination deficiency (HRD) test to measure three modes of HRD; and myPlan lung cancer, an RNA expression test for lung cancer. Myriad Genetics, Inc. has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Read More
How much money does Myriad Genetics Inc make?
News & Events about Myriad Genetics Inc.
Globe Newswire
27days ago
Myriad Genetics continues to advance non-invasive prenatal screening with Prequel and the forthcoming FirstGene test using AMPLIFY technology SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced ...
Globe Newswire
28days ago
SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan (...
Globe Newswire
1month ago
Myriads MyRisk Hereditary Cancer test with RiskScore provides a personalized breast cancer risk assessment for women of all ancestriesSALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.(NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results ...
Globe Newswire
3 months ago
$67.5 million tuck-in acquisition strengthens Myriads Womens Health portfolio of prenatal productsFast-growing SneakPeek test has helped 750,000 parents learn babys gender from home earliest method to date at 6 weeks into pregnancy SALT LAKE CITY, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, ...
Globe Newswire
3 months ago
Highlights: Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3 million), change of estimates1 ($5.3 million). Third quarter testing volumes, excluding divested businesses, grew 12% year...
Frequently Asked Questions
Frequently Asked Questions
What is Myriad Genetics Inc share price today?
plus_minus_icon
Can Indians buy Myriad Genetics Inc shares?
plus_minus_icon
How can I buy Myriad Genetics Inc shares from India?
plus_minus_icon
Can Fractional shares of Myriad Genetics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Myriad Genetics Inc stocks?
plus_minus_icon
What is today’s traded volume of Myriad Genetics Inc?
plus_minus_icon
What is today’s market capitalisation of Myriad Genetics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Myriad Genetics Inc?
plus_minus_icon
What percentage is Myriad Genetics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Myriad Genetics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$19.72
$0.46
(2.39%)
logo-mygn
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00